

# RAUCON *BD Executive News*

Vol. 16 # 4 | 5 March 2020

## Hot Company News

\* Licensing: **Laboratorios Almirall, S.A.** entered into a License Agreement for **Seysara®** in China. **Seysara®** (sarecycline) is an innovative first in class tetracycline-derived oral antibiotic for the treatment of inflammatory lesions of moderate to severe nonnodular acne vulgaris, is expected to be submitted to NMPA in 2023. Almirall has the commercialisation rights for the medicine in the US, and will develop it for acne in China under a License Agreement from **Paratek Pharmaceuticals, Inc.** 24 Feb 2020 (www.almirall.es)

\* Commercialisation: **Aptorum Group Limited**, a pharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announced the commercialisation of its dietary supplement for women undergoing menopause and experiencing related symptoms. The supplement is made with the bioactive ingredient extracted Chinese yam powder containing "DOI", which is Aptorum Group's non-hormonal approach intended to meet certain growing consumer nutritional trends and concerns. 24 Feb 2020 (www.aptorumgroup.com)

\* Acquisition: **Asahi Kasei Corp.** has completed its acquisition of **Veloxis Pharmaceuticals Inc.**, assuming full ownership of Veloxis on March 3, 2020 (CET). 4 Mar 2020 (www.asahi-kasei.co.jp)

\* Distribution: **Beximco Pharmaceuticals Limited** signed a distribution agreement **Mylan** through which Beximco will gain exclusive rights to launch Mylan's portfolio of key monoclonal antibodies to treat different types of cancers and other conditions throughout Bangladesh. The first product Beximco will launch is Mylan's breast cancer drug **Ogivri™** - a biosimilar based on Roche's blockbuster drug **Herceptin**. 24 Feb 2020 (www.beximco-pharma.com)

\* Acquisition: **Domain Therapeutics**, a biopharmaceutical company acquired all shares in **PC SAS (Prestwick Chemical)** and **Neurofit SAS**, two former subsidiaries of **Bionomics Ltd**, an Australian company. 3 Mar 2020 (www.domain-therapeutics.com)

\* Acquisition: **Gilead Sciences, Inc.** and **Forty Seven, Inc.** have entered into a definitive agreement for Gilead to acquire Forty Seven. The transaction values Forty Seven at approximately \$4.9 billion. 2 Mar 2020 (www.gilead.com)

\* Divestiture: **Merck KGaA** signed an agreement to sell its allergy business **Allergopharma** to **Dermapharm Holding SE**. The transaction, which is expected to close by the end of the second quarter 2020, is subject to regulatory approval and satisfaction of other customary closing conditions. Allergopharma is a leader in allergen-specific immunotherapy of type 1 allergies such as hay fever or allergic asthma. In 2018, Allergopharma generated sales of € 88 million. Financial terms of the transaction were not disclosed. 19 Feb 2020 (www.merck.de)

\* Acquisition: **Neuraxpharm Group** acquired **Glenmark's** CNS product portfolio in Poland. Following the transaction, the Glenmark CNS commercial team in Poland will join Neuraxpharm Polska's existing sales and marketing organisation to create a strong player in the Polish CNS market, with excellent access to psychiatrists, neurologists and pharmacies. Glenmark's established portfolio of 20 proprietary CNS products in Poland comprise both prescription medicines and Consumer Healthcare products. Lead products include the branded generics **Cital®** and **Lamotrix®**, both relevant brands in their respective markets. Financial terms of the transaction were not disclosed. 25 Feb 2020 (www.neuraxpharm.com)

\* Acquisition: **Perrigo Company**

**plc** has reached a definitive agreement to acquire the oral care assets of **High Ridge Brands** for \$113 million in cash. The acquisition, which is subject to bankruptcy court approval in connection with High Ridge Brands' chapter 11 cases, as well as other customary closing conditions, is expected to close in the first quarter of 2020. 24 Feb 2020 (www.perrigo.com)

\* Acquisition: **RedHill Biopharma Ltd.**, a specialty biopharmaceutical company primarily focused on the commercialisation and development of proprietary drugs for the treatment of gastrointestinal diseases, is acquiring the global rights to **Movantik®** (naloxegol) 1, excluding Europe, Canada and Israel, from **AstraZeneca**. The acquisition is expected to close in the first quarter of 2020, subject to customary closing conditions and regulatory clearances. **Movantik®** is a peripherally acting mu-opioid receptor antagonist indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain. 25 Feb 2020 (www.redhillbio.com)

\* Acquisition: **Stada AG** expands its global OTC business agreeing to acquire a portfolio of well-established local and regional consumer healthcare brands from **GlaxoSmithKline (GSK)** in countries predominantly in Europe including France, Germany, Italy, Poland, Russia, Spain and Switzerland. The transaction represents 15 brands including **Venoruton**, for venous treatment; **Coldrex** cold remedy; **Cetebe** vitamin C supplements; **Mebucaine** sore throat range and **Tavegyl** allergy brand. These five brands account for just over half of the acquired brands' combined turnover. From a geographic perspective, sales of the GSK Consumer Healthcare portfolio being acquired by STADA are distributed broadly, with Germany, Russia, Poland and Spain each accounting for more than a tenth of portfolio turnover. Also among

the top 10 countries by portfolio sales are France, Hungary, Italy, Portugal, Serbia and Switzerland, further enhancing STADA's position as a truly pan-European consumer healthcare player. The transaction is subject to customary conditions and is expected to close in Q2 2020. No financial details will be disclosed. 24 Feb 2020 (www.stada.com)

\* Acquisition: **Takeda Pharmaceutical Company Limited** has acquired **PvP Biologics, Inc.** Takeda exercised its option to acquire **PvP Biologics** for a pre-negotiated upfront payment as well as development and regulatory milestones totalling up to \$330 million. 26 Feb 2020 (www.takeda.co.jp)

\* Co-Development: **Tetra Bio-Pharma Inc.**, a company active in cannabinoid-derived drug discovery and development, is pleased to announce that it has signed a co-development definite agreement with **MAKScientific**. This agreement provides Tetra with access to novel patented new molecules with CB1 and CB2 agonist or antagonist properties. 27 Feb 2020 (www.tetrabiopharma.com)

## BD People on the Move

\* Basic Pharma Group: **Manon Emonts**, who has been Business Development Officer, left the company. (Pers Comm 20 Feb 2020)

\* Cosmo Pharmaceuticals N.V.: **Sean MacDonald**, who joined Cosmo in April 2019 and was VP and Head of Corporate & Business Development of Pharmascience in Canada, has been named Head of Business Development. (Press Release 24 Feb 2020)

\* Equillum, Inc.: **Matthew Ritter**, Ph.D., joining from La Jolla Pharmaceutical Company where he was head of business development has been hired as vice president of corporate development (Press Release 27 Feb 2020)